Literature DB >> 20580684

Parathyroid hormone and bisphosphonate have opposite effects on stress fracture repair.

Ashley V Sloan1, Joseph R Martin, Shuo Li, Jiliang Li.   

Abstract

This study was aimed to investigate the effects of Parathyroid hormone (PTH) and alendronate (ALN) on stress fracture repair. Stress fractures were induced in the ulnae of female adult rats. Animals were treated daily with vehicle, PTH (40 microg/kg) or alendronate (2 microg/kg), respectively. Bone mineral content (BMC) and bone mineral density (BMD) of bilateral ulnae were measured at two, four and eight weeks following induction of stress fracture. Histology at the ulna midshaft was undertaken at 2 and 4 weeks and mechanical testing was done at 8 weeks after stress fracture. PTH increased BMC significantly by 7% at 4 weeks and BMD and BMC significantly by 10% and 7% at 8 weeks compared to the control. Alendronate did not change BMD or BMC in comparison with the control. PTH significantly stimulated bone formation by 114% at 2 weeks, increased intracortical resorption area by 23% at 4 weeks, and enhanced the ultimate force of the affected ulnae by 15% at 8 weeks compared to the control. Alendronate significantly suppressed bone formation rate by 44% compared to the control at 4 weeks. These data indicate that PTH may accelerate intracortical bone remodeling induced by microdamage and alendronate may delay intracortical bone remodeling during stress fracture repair in rats. This study suggests that PTH may be used to facilitate stress fracture repair whereas bisphosphonates may delay tissue level repair of stress fractures. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20580684     DOI: 10.1016/j.bone.2010.05.015

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  23 in total

Review 1.  Atypical femoral fractures: epidemiology, etiology, and patient management.

Authors:  Eve Donnelly; Anas Saleh; Aasis Unnanuntana; Joseph M Lane
Journal:  Curr Opin Support Palliat Care       Date:  2012-09       Impact factor: 2.302

Review 2.  Anabolic agents: what is beyond osteoporosis?

Authors:  Y Liu; A E Levack; E Marty; O Or; B P Samuels; M Redko; J M Lane
Journal:  Osteoporos Int       Date:  2018-04-07       Impact factor: 4.507

3.  Teriparatide for the rapid resolution of delayed healing of atypical fractures associated with long-term bisphosphonate use.

Authors:  Silvina R Mastaglia; Gabriel Aguilar; Beatriz Oliveri
Journal:  Eur J Rheumatol       Date:  2015-08-21

4.  [Atypical subtrochanteric femur fracture under alendronate therapy in spite of an intramedullar implant].

Authors:  H-P Sobotta; T Gösling
Journal:  Unfallchirurg       Date:  2017-02       Impact factor: 1.000

5.  Development of an in vivo bone fatigue damage model using axial compression of the rabbit forelimb.

Authors:  Evan G Buettmann; Matthew J Silva
Journal:  J Biomech       Date:  2016-08-25       Impact factor: 2.712

Review 6.  Effects of anti-osteoporosis medications on fracture healing.

Authors:  Niklas R Jørgensen; Peter Schwarz
Journal:  Curr Osteoporos Rep       Date:  2011-09       Impact factor: 5.096

7.  Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.

Authors:  Joseph D Isaacs; Louis Shidiak; Ian A Harris; Zoltan L Szomor
Journal:  Clin Orthop Relat Res       Date:  2010-08-31       Impact factor: 4.176

Review 8.  Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw.

Authors:  J Compston
Journal:  Osteoporos Int       Date:  2011-10-14       Impact factor: 4.507

9.  Management strategy for symptomatic bisphosphonate-associated incomplete atypical femoral fractures.

Authors:  Anas Saleh; Vishal V Hegde; Anish G Potty; Robert Schneider; Charles N Cornell; Joseph M Lane
Journal:  HSS J       Date:  2012-05-02

Review 10.  How do bisphosphonates affect fracture healing?

Authors:  Stephen L Kates; Cheryl L Ackert-Bicknell
Journal:  Injury       Date:  2016-01       Impact factor: 2.586

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.